BioNTech (BNTX) reported Q4 earnings Monday of 1.08 euros ($1.17) per diluted share, down from 1.88 euros a year earlier.
Comparable analyst estimates were not readily available.
Revenue for the quarter ended Dec. 31 was 1.19 billion euros, down from 1.48 billion euros a year earlier.
Analysts surveyed by FactSet expected 1.09 billion euros.
For 2025, the biotech firm expects revenue of 1.70 billion euros to 2.20 billion euros. Analysts polled by FactSet expect 2.54 billion euros.
Shares of the company were down more than 2.6% in recent premarket activity Monday.
Price: 106.00, Change: -2.78, Percent Change: -2.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.